(NASDAQ: AVDL) Avadel Pharmaceuticals's forecast annual revenue growth rate of 24.45% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Avadel Pharmaceuticals's revenue in 2025 is $221,075,000.On average, 4 Wall Street analysts forecast AVDL's revenue for 2025 to be $26,615,142,533, with the lowest AVDL revenue forecast at $26,478,526,155, and the highest AVDL revenue forecast at $26,692,140,961. On average, 5 Wall Street analysts forecast AVDL's revenue for 2026 to be $34,779,597,509, with the lowest AVDL revenue forecast at $33,873,676,537, and the highest AVDL revenue forecast at $36,732,036,834.
In 2027, AVDL is forecast to generate $41,004,818,438 in revenue, with the lowest revenue forecast at $38,617,672,983 and the highest revenue forecast at $44,393,040,551.